Dow Jumps Over 600 Points; Constellation Energy Posts Upbeat Earnings
U.S. stocks rallied Monday, led by tech and consumer discretionary shares. Constellation Energy beat Q3 estimates; oil fell while gold rose.
Stocks · News reference
Faeth Therapeutics Announces Data From Its Phase 2 Study Of PIKTOR Shows Confirmed Objective Response Rate OF 33%, Disease Control Rate Of 83%
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Faeth Therapeutics, Inc. (FTH)
Filed: 2026-11-09 AccNo: 0001193125-26-452755 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Faeth Therapeutics Appoints Adam Schayowitz to Board of Directors
Faeth Therapeutics, a subsidiary of Sensei Biotherapeutics, has appointed Adam Schayowitz, Ph.D., MBA, to its Board of Directors.
William Blair Initiates Coverage On Faeth Therapeutics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating.
Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70
Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.
LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $59.